Increasing prevalence of cardiovascular diseases, technological advancements and shortage of donor organs for transplantation drive the growth of the global ventricular assisted devices market.

PORTLAND, Ore., May 14, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Ventricular Assist Devices Market By Product (Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), and Biventricular Assist Devices (BIVADs)), Application (Bridge-To-Transplant (BTT), Destination Therapy, Bridge-To-Recovery (BTR), and Bridge To Candidacy Therapy), Design (Transcutaneous Ventricular Assist Devices and Implantable Ventricular Assist Devices), and Age (Adults and Pediatrics): Global Opportunity Analysis And Industry Forecast, 2024-2035". According to the report, the global ventricular assisted devices market was valued at $1.6 billion in 2023 and is estimated to reach $4.1 billion by 2035, exhibiting a CAGR of 8.1% from 2023 to 2035.

Request Sample of the Report on Ventricular Assisted Devices Market Forecast 2035- https://www.alliedmarketresearch.com/request-sample/2024 

Prime determinants of growth

Rise in adoption of ventricular assisted devices, advancements in technologies, and presence of key players are factors that drive the growth of the global ventricular assisted devices market. However, high cost of devices and procedures is anticipated to hinder the market growth. Moreover, rise in healthcare expansion is expected to offer remunerative opportunities for the ventricular assisted devices market during the forecast period.

Report coverage & details:

Want to Explore More, Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/2024 

The left ventricular assist devices (LVADs) segment to maintain its lead position during the forecast period.

By product, the left ventricular assist devices segment registered the largest share in 2023, accounting for more than three-fourths of the global ventricular assisted devices market revenue and is projected to register the highest CAGR of 8.2% during the forecast period. This increase in adoption of LVADs is mainly attributed as it is used more commonly than RVADs for several reasons such as the left ventricle is the main pumping chamber of the heart and providing support to the left ventricle can have a significant impact on overall heart function. Furthermore, heart failure is typically caused by dysfunction in the left ventricle, so LVAD can address the root cause of the condition. In addition, the availability of LVADs and the preference over RVAD device owing to their safety and efficacy is further contributing to the segment growth.

The bridge-to-transplant (BTT) segment to maintain its lead position during the forecast period.

By application, the bridge-to-transplant (BTT) segment registered the largest share in 2023, accounting for nearly two-fifths of the global ventricular assisted devices market revenue, owing to rise in awareness among people regarding bridge-to-transplant therapy, which has significantly increased the success rate of transplant surgeries.

However, the destination therapy segment is projected to register the highest CAGR of 9.3% during the forecast period as VADs have become a prominent solution for people with heart failure and for those who are ineligible for heart transplantation.

The implantable ventricular assist devices segment to maintain its lead position during the forecast period.

By design, the implantable ventricular assist devices segment accounted for the largest share in 2023, accounting for more than 90% of the global ventricular assisted devices market revenue and is projected to register highest CAGR of 8.1% during the forecast period owing to the rising prevalence of epilepsy worldwide and increasing adoption of deep brain stimulation as an effective treatment option for drug-resistant epilepsy, contributing to the segment's accelerated growth trajectory.

The adults segment to maintain its lead position during the forecast period.

By age, the adults segment accounted for the largest share in 2023, accounting for more than 90% of the global ventricular assisted devices market revenue and is projected to register the highest CAGR of 8.2% during the forecast period owing to technological advancements in the field of VADs and development of pediatric VADs that are highly efficient in treating heart failure in pediatric patients.

For Purchase Enquiry- https://www.alliedmarketresearch.com/purchase-enquiry/2024 

North America to maintain its dominance by 2035

Region-wise, North America held the highest market share in terms of revenue in 2023, accounting for nearly half of the global ventricular assisted devices market revenue. This is primarily attributed to rise in prevalence of heart failure, high adoption of technologically advanced ventricular assist devices, developed healthcare infrastructure, and increase in patient awareness about the availability of treatment options for heart failure.

However, the Asia-Pacific segment is projected to register the highest CAGR of 10.7% during the forecast period. This is attributed to the surge in demand for sophisticated ventricular assist devices, large number of healthcare reforms, high prevalence of cardiac disorders, and increase in focus of key players to develop technologically advanced & cost-effective devices.

Leading Market Players: -

• Evaheart Inc.
• Abiomed Inc.
• Abbott Laboratories
• CH Biomedical Inc.
• Carmat SA
• Bivacor Inc.
• LivaNova PLC
• Berlin Heart GmbH
• Fineheart
• AdjuCor GmbH

The report provides a detailed analysis of these key players of the global ventricular assisted devices market. These players have adopted different strategy such product launch, product development, and product approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com  
Follow Us on: LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/ventricular-assisted-devices-market-to-reach-4-1-billion-globally-by-2035-at-8-1-cagr-allied-market-research-302144562.html